This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Default Category
-
Cancer Screening in Japan: Market Research and Segmentation
Quelch, John A.; Rodriguez, MargaretCase HBS-514057-EMarketingSince founding CancerScan in 2008, Jun Fukuyoshi and Yoshiki Ishikawa had helped to improve cancer screening rates in Japan. Between 2005 and 2007, awareness of breast cancer in Japan rose from 55% to 70%, but the incidence of breast cancer screenings remained constant. Jun and Yoshiki applied marketing research techniques to increase the screening rate for breast cancer, a disease which killed over 12,000 Japanese women in 2011. Cancer screening...Starting at €8.20
-
Vision 2020: Takeda and the Vaccine Business
Quelch, John A.; Rodriguez, MargaretCase HBS-514084-EMarketingTo maximize their effectiveness, color cases should be printed in color. In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003 and chief executive in 2009. By 2013, Takeda was in the midst of implementing its new Vision 2020 plan, a s...Starting at €8.20
-
GlaxoSmithKline in China (A)
Quelch, John A.; Rodriguez, MargaretCase HBS-514049-EMarketingFour GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to local customs while still observing local laws.Starting at €8.20
-
GlaxoSmithKline in China (B)
Quelch, John A.; Rodriguez, MargaretCase HBS-514050-EMarketingIn 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later, GSK's CEO, Andrew Witty, called the allegations "shameful" and said the company would use the opportunity to "make changes."Starting at €5.74
-
GlaxoSmithKline in China (C)
Quelch, John A.; Rodriguez, MargaretCase HBS-514092-EMarketingThis case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.Starting at €5.74